Can viral vector-mediated therapies provide long-term motor stability?

The premise of gene therapy in Parkinson's involves re-programming cells in the striatum to produce dopamine or neurotrophic factors. Unlike chronic drug regimens, these interventions aim to offer durable, multi-year relief from symptoms with a single procedure, fundamentally altering the economics of healthcare reimbursement.

Is the Gene Therapy for Neurodegenerative Disorders market reaching maturity?

While still considered "emerging," the Gene Therapy for Neurodegenerative Disorders segment has seen massive capital inflows in late 2023 and 2024. Strategic partnerships are focusing on AAV-based vectors that target the GBA1 gene, which is the most common genetic risk factor for Parkinson’s. This focus on specific genetic markers is the primary trend for 2025.

Cost-benefit analysis of curative vs. palliative models

The high upfront cost of gene therapy (potentially reaching seven figures per patient) poses a challenge for payers. However, the reduction in long-term nursing home costs and secondary complications makes a compelling case for value-based pricing models that spread payments over several years.

• AAV-based delivery of GAD (Glutamic Acid Decarboxylase).
• Growth in GDNF (Glial Cell Line-Derived Neurotrophic Factor) trials.
• Expansion of CRISPR/Cas9 applications for inherited Parkinson's variants.

Future Outlook 2024-2025

By 2025, we expect to see the first Phase II results for next-generation gene therapies that use non-invasive delivery methods, potentially eliminating the need for intracranial surgery and expanding the addressable patient population.

Author: Sofiya Sanjay

Designation: Healthcare Research Consultant, Market Research Future

About: At Market Research Future (MRFR), we enable organizations to unravel complex industries through Cooked Research Reports (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. Our studies across products, technologies, applications, end users, and global to country-level segments help decision-makers see more, know more, and do more.

Contact: 99 Hudson Street, 5th Floor, New York, NY 10013, USA | (855) 661-4441 (US) | +44 1720 412 167 (UK) | +91 2269738890 (APAC) | [email protected]